How are Cochlear shares impacted by Trump's tariffs?

Will the company escape from the tariffs? Let's find out.

| More on:
a young woman holds her hand to her ear and leans sideways as if to listen to something that's surprising her as her eyes and her mouth are wide open.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Cochlear Ltd (ASX: COH) shares have been bouncing around on Thursday.

In morning trade, the hearing solutions company's shares were down as much as 4.5% to $256.43.

But this afternoon, they have started to recover and currently sit 0.5% lower for the day at $266.74.

What is going on with Cochlear shares?

The company's shares were caught up in a broad market selloff this morning after US President Donald Trump made his big announcement.

From Saturday, the United States will put a minimum 10% tariff on foreign imports, including those from Australia, as part of what Trump has dubbed his "liberation day" economic plan.

This has been bad news for a number of ASX shares, such as Ansell Ltd (ASX: ANN), Breville Group Ltd (ASX: BRG), Lovisa Holdings Ltd (ASX: LOV), and Cettire Ltd (ASX: CTT). They have all fallen heavily today amid concerns over the impact that the trade tariffs could have on their respective businesses.

But what about Cochlear? How will it be impacted?

Well, the short answer is we don't know yet. Until greater detail is provided, Cochlear advised that it is unsure what the impact will be. However, there is reason to hope that the impact will not be material. This may explain why Cochlear shares have recovered from their intraday lows this afternoon.

Cochlear response

This morning, Cochlear released an announcement, explaining that it was a complex situation. It said:

There are complexities in understanding the application of the new tariff. Cochlear has long been importing its products under a chapter of the Harmonized Tariff Schedule of the United States that provides for duty-free importation on a range of products into the US, including hearing implants. We are expecting further detail in the US Customs and Border Protection Notice of Implementation, which is expected to be published in the next week. An update will be provided to the market in due course.

Judging by the way that Cochlear's shares have recovered today, it seems that some investors believe that the company will escape from the wrath of Trump's tariffs. Though, that will not be known for sure until the company releases a follow up announcement next week or the week after.

For now, the team at Citi are likely to see recent weakness as a buying opportunity. A note from last month reveals that the broker has a buy rating and $300.00 price target on the company's shares.

Citigroup is an advertising partner of Motley Fool Money. Motley Fool contributor James Mickleboro has positions in Cochlear and Lovisa. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear and Lovisa. The Motley Fool Australia has recommended Ansell, Cochlear, and Lovisa. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

3 reasons to buy this quality ASX 200 healthcare share today

A leading expert expects this outperforming ASX 200 healthcare share will keep running hot.

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Healthcare Shares

Brokers tip 4 ASX 200 healthcare shares to buy now

Healthcare is a defensive sector that can provide useful cover for investors when the market is volatile.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

How Trump's tariffs have created 'upside potential' for CSL shares

A leading expert says CSL shares are now looking ‘cheap’.

Read more »

Shot of a young scientist looking stressed out while working on a computer in a lab.
Healthcare Shares

Telix shares crash 8% on US FDA blow

This high-flying stock has been hit with some bad news.

Read more »

A man wakes up happy with a smile on his face and arms outstretched.
Healthcare Shares

ResMed shares jump 8% on strong Q3 update

It was yet another strong quarter from this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX All Ords stock is up 10% on big news

This high-flying stock just can't stop rising. What's going on?

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

Telix shares rocket 15% on stellar Q1 sales update

Let's see how the company performed during the three months.

Read more »

Portrait, confidence and team of doctors in the hospital standing after a consultation or surgery. Success, healthcare and group of professional medical workers in collaboration at a medicare clinic.
Healthcare Shares

Macquarie's top 3 ASX stock picks in the healthcare sector

Top broker has revealed 3 healthcare stocks with upside. 

Read more »